The Return of C-Peptide: Why This Old Biomarker Is Finding New Clinical Uses

For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, clinicians use C-peptide measurements to estimate residual insulin production, predict long-term complications, select appropriate therapies, and even identify patients who may benefit from emerging disease-modifying treatments.

Like checking the fuel gauge rather than simply asking whether a car starts, C-peptide offers a clearer picture of how much insulin-producing capacity remains. Consequently, this biomarker is becoming increasingly important in personalized diabetes management. This article explores why C-peptide has regained attention, the latest clinical evidence supporting its use, and where it may fit into routine diabetes care.

Table of Contents

• Understanding C-peptide and its role
• Why C-peptide matters beyond diagnosis
• New research and evolving clinical applications
• Practical considerations for clinicians
• Conclusion
• Frequently Asked Questions

Understanding C-Peptide and Beta-Cell Function

C-peptide is released when proinsulin is split into insulin and connecting peptide before secretion from pancreatic beta cells. Because insulin and C-peptide are produced in equal amounts, measuring C-peptide provides a reliable estimate of endogenous insulin production.

Unlike insulin, C-peptide is not significantly affected by hepatic first-pass metabolism. Therefore, blood concentrations tend to remain more stable and provide a more accurate reflection of pancreatic insulin secretion. This makes C-peptide testing for people with diabetes especially useful in patients receiving exogenous insulin, where serum insulin measurements may be misleading.

Traditionally, clinicians used fasting or stimulated C-peptide levels to distinguish autoimmune diabetes from insulin-resistant diabetes. Patients with type 1 diabetes generally have very low or absent C-peptide levels, while those with type 2 diabetes often retain measurable insulin production. Nevertheless, researchers now recognize that many people with longstanding type 1 diabetes continue to produce small amounts of insulin for years after diagnosis.

This residual beta-cell activity appears to have important clinical implications. Even low levels of endogenous insulin production have been associated with improved glycemic stability and fewer diabetes-related complications.

Why C-Peptide Testing Is Becoming More Valuable

Modern diabetes care increasingly emphasizes individualized treatment. As a result, clinicians need better tools to determine which therapies are most appropriate for each patient. C-peptide provides objective information that can guide these decisions.

Several studies have shown that preserved C-peptide levels are associated with lower rates of severe hypoglycemia. Patients with remaining beta-cell function often experience more predictable glucose control because endogenous insulin secretion still responds, at least partially, to changing glucose levels.

Furthermore, higher C-peptide levels have been linked to reduced risk of microvascular complications, including diabetic retinopathy and nephropathy. Although glycemic control remains the primary driver of complication risk, residual insulin secretion appears to provide additional protective benefits.

C-peptide testing may also help identify patients with latent autoimmune diabetes in adults (LADA). Since these individuals often present similarly to type 2 diabetes, measuring C-peptide alongside diabetes autoantibodies can improve diagnostic accuracy and support earlier initiation of appropriate therapy.

Another growing application involves selecting patients for advanced technologies. For example, residual beta-cell function may influence outcomes with hybrid closed-loop insulin delivery systems and other automated insulin technologies.

As disease-modifying therapies continue to emerge for type 1 diabetes, including immune-targeted treatments, C-peptide is increasingly used as both an eligibility criterion and an outcome measure in clinical trials. Preserving endogenous insulin production has become an important therapeutic goal rather than simply delaying complete beta-cell loss.

Emerging Research and Future Clinical Applications

Recent research has expanded interest in C-peptide testing across diabetes care beyond traditional endocrinology. Investigators are examining how C-peptide measurements may predict treatment response across multiple forms of diabetes.

In people with type 2 diabetes, preserved C-peptide levels may predict better responses to GLP-1 receptor agonists and SGLT2 inhibitors before insulin becomes necessary. Conversely, patients with low C-peptide concentrations may require earlier insulin intensification.

Researchers are also exploring whether serial C-peptide measurements can monitor disease progression over time. Instead of relying only on HbA1c, clinicians may soon use declining C-peptide levels to identify accelerating beta-cell failure before glucose control worsens significantly.

The TrialNet network and other research groups continue to use stimulated C-peptide as a primary endpoint in studies evaluating interventions designed to preserve beta-cell function after type 1 diabetes diagnosis. Because even modest preservation appears clinically meaningful, maintaining C-peptide has become an increasingly important research objective.

Interest has also grown in the biological activity of C-peptide itself. Earlier it was considered biologically inactive. However, experimental studies suggest that C-peptide may influence endothelial function, nerve health, and microvascular circulation. While these findings remain under investigation, they have renewed scientific interest in the molecule beyond its role as a biomarker.

Professional organizations continue to refine recommendations regarding C-peptide testing. Although routine testing is not yet recommended for every patient with diabetes, selective use is becoming more common in cases involving uncertain diabetes classification, insulin dependence, or consideration of advanced therapies.

For clinicians seeking additional evidence-based diabetes updates, Diabetes in Control offers ongoing coverage of emerging biomarkers, therapeutic advances, and clinical practice recommendations. Additional guidance regarding laboratory interpretation is also available from the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases.

Practical Considerations for Everyday Clinical Practice

Choosing the appropriate C-peptide test depends on the clinical question being asked. Fasting C-peptide measurements are widely available and relatively inexpensive. However, stimulated testing using mixed-meal tolerance tests or glucagon stimulation often provides greater sensitivity when assessing residual beta-cell function.

Interpretation should always consider the patient’s current glucose level because insulin secretion depends on ambient blood glucose. Measuring C-peptide during hypoglycemia may underestimate pancreatic function.

Renal impairment also requires careful interpretation since reduced kidney function decreases C-peptide clearance and may artificially elevate measured concentrations.

Clinicians should remember that C-peptide represents only one component of comprehensive diabetes evaluation. It complements, rather than replaces, clinical history, diabetes autoantibody testing, HbA1c measurements, continuous glucose monitoring data, and assessment of insulin resistance.

As precision medicine continues to evolve, combining multiple biomarkers will likely provide the greatest clinical benefit. C-peptide testing in diabetes care appears well positioned to become one of the central laboratory tools supporting individualized diabetes management.

Conclusion

C-peptide has evolved from a relatively simple diagnostic marker into an increasingly valuable tool for modern diabetes management. Today, C-peptide testing helps clinicians assess residual beta-cell function, refine diabetes classification, estimate complication risk, and personalize treatment decisions. As new therapies aimed at preserving insulin production become available, the importance of C-peptide testing in diabetes care will likely continue to grow. Rather than representing an outdated laboratory measurement, C-peptide has become an essential biomarker supporting the shift toward precision diabetes care.

Frequently Asked Questions

What is C-peptide in diabetes?

C-peptide is a protein released when the pancreas produces insulin. Measuring it helps estimate how much insulin the body makes naturally.

Why is C-peptide testing important?

It helps distinguish diabetes types, evaluate remaining beta-cell function, guide treatment decisions, and identify patients who may benefit from specific therapies.

Can people with type 1 diabetes still have detectable C-peptide?

Yes. Many individuals retain small amounts of endogenous insulin production for years after diagnosis, and this residual function may improve clinical outcomes.

When should clinicians order a C-peptide test?

Testing is particularly useful when diabetes classification is uncertain, before initiating complex insulin regimens, when evaluating LADA, or when considering advanced diabetes technologies or clinical trials.

Does C-peptide replace HbA1c testing?

No. C-peptide measures insulin production, whereas HbA1c reflects long-term glucose control. Both provide complementary clinical information.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.